SMOKING
(See also SMOKE, TOBACCO; SMOKE INHALATION: SMOKING, CIGAR; SMOKING, PIPE; SNUFF DIPPING; TOBACCO CHEWING)

air pollution and chronic obstructive lung disease and, 6:37
and air pollution in lung neoplasm etiology, 5:25-27
allergy and, summary of findings, 1:23-24
antitrypsin deficiency and risk for chronic obstructive lung disease, 6:33-34
bladder neoplasms and, summary of findings, 1:17
bladder neoplasms in coal gas workers and, 7:16
bronchitis and, summary of findings, 1:18
bronchopulmonary diseases and, summary of findings, 1:18-19
cardiovascular diseases and, summary of findings, 1:18-15
chronic obstructive lung disease and, 6:7
chronic obstructive lung disease and mortality, 6:9
coronary heart disease and, 4:21
effect of childhood respiratory symptoms on adult respiratory tract disease, 6:38-39
effect of combined tobacco product use on mortality ratio, 2:35-36, 2:39
effect on absenteeism, 3:8, 3:10
effect on absenteeism, summary of findings, 1:12-13
effect on acrolein content in enclosed spaces, 11:25
effect on activity limitation, 3:13-14
effect on angina pectoris, 4:47
effect on aryl hydrocarbon hydroxylase activity, 5:57
effect on asthmatic patients, 10:21-22, 21:22
effect on benzo(a)pyrene content in enclosed spaces, 11:24
effect on carbohydrate metabolism, 12:66
effect on carboxyhemoglobin levels, 15:29-30
effect on cardiovascular system, 12:15-16, 15:19
effect on catecholamine levels in plasma, 14:88
effect on cause-specific mortality ratio, 2:37-41
effect on central nervous system, 15:18-19
effect on cerebrovascular disease risk, 4:50
effect on corticosteroid secretion, 12:40
effect on dimethylnitrosamine content in enclosed spaces, 11:25
effect on drug assays, 12:34
effect on enzyme activity, 1:25-26
effect on esophagus, 5:44, 13:26
effect on furosemide diuretic action, 12:54
effect on gastric secretion in man and animals, 9:12
effect on gastric secretion in peptic ulcer patients, 9:13-14
effect on hormones, 12:20
effect on imipramine pharmacokinetics, 12:33
effect on immune system, 10:14-20
effect on immune system, summary of findings, 1:18-19, 1:23-24, 1:26
effect on incidence of acute conditions, 3:6, 3:9
effect on incidence of chronic conditions, 3:6-7
effect on learning, 15:18-19
effect on levels of carbon monoxide in expired air, 15:30
effect on lipid metabolism, 12:65
effect on lung function, 6:22
effect on lung function, summary of findings, 1:18
effect on lung neoplasm histologic type, 5:23-24
effect on lung cancer, summary of findings, 1:18-19
effect on morbidity, 3:5
effect on mortality in the United States, 2:9
effect on mortality in women, 2:25
effect on mortality ratios, summary of findings, 1:10-12
effect on pancreatic secretion, 9:14-15
effect on pesticide residue levels, 12:75
effect on peptic ulcer healing and recurrence, 9:8-9
effect on pharmacodynamics and pharmacokinetics, 12:27-44
effect on pharmacodynamics and pharmacokinetics, summary of findings, 1:25-26
effect on phenol red excretion, 12:39
effect on protein binding of drugs, 12:40
effect on protein metabolism, 12:65-66
effect on pyloric pressure, 9:15
effect on respiratory symptoms in children, 6:11-12
effect on responses to diagnostic tests, summary of findings, 1:26
effect on salivary secretory IgA levels, 10:17
effect on secretin release, 9:15-16
effect on sleep, 13:11
effect on small airways function, 6:14-19
effect on small airways pathology, 6:24, 6:27
effect on vitamin B₉ levels, 12:67
effect on vitamin B₁₂ levels, 12:66
effect on vitamin C levels, 12:66
emphysema and, 6:24-26
emphysema and, summary of findings, 1:18-19
esophageal neoplasms and, summary of findings, 1:17
heredity and mortality and, 2:41
interactive effect with occupational exposure, summary of findings, 1:19-20
kidney neoplasms and, summary of findings, 1:17
laryngeal neoplasms and, summary of findings, 1:16-17
lung neoplasms and, summary of findings, 1:16
lung pathology at autopsy in smokers vs nonsmokers, 6:18
methods for measuring usage, 15:29-31
myocardial infarct and, 4:21
in myocardial infarct etiology, 4:38-40
neoplasms and, summary of findings, 1:15-17
and occupational exposure in lung neoplasm etiology, 27:29
and occupational hazards recommendations for research, 7:19
oral neoplasms and, summary of findings, 1:17
pancreatic neoplasms and, summary of findings, 1:17
peptic ulcer and, summary of findings, 1:23
in peptic ulcer etiology, 9:11-12
percent distribution of cigar, cigarette and pipe smokers in the United States, 13:9
in polycythemia etiology, 12:83
respiratory symptoms and, summary of findings, 1:18-19
respiratory tract diseases in children and, 6:11
as risk factor for chronic obstructive lung disease, research recommendations, 6:41-42
as risk factor for bladder neoplasms after exposure to aromatic amines, 7:16
standard conditions in the United States, 14:35
in sudden cardiac death etiology, 4:44-45
susceptibility to infections and, 10:19
synergistic effect with uranium on respiratory tract, 12:90

SMOKING AND HEALTH
Advisory Committee to the Surgeon General on Smoking and Health, historical perspective, 1-5-10
effect of lifestyle, 3:11
history of research, 1-5-10
occupational hazards, 7:8

SMOKING, BIDIS
leukoplakia and, 5:41

SMOKING CHARACTERISTICS
effect of nicotine, 15:12
effect on arsenic levels in the respiratory tract, 14:57
effect on dependence, 14:97, 15:25
effect on nicotine absorption, 14:87
males vs. females, 5:21, 5:23
survey, respondent-reported styles,
A:21-22
research issues, A:22

SMOKING, CIGAR
(See also CIGARS; SMOKE, CIGAR; SMOKERS, CIGAR; TOBACCO, CIGAR)
bronchopulmonary diseases and, summary of findings, 1:28
in cardiovascular disease etiology, 13:32-34
cardiovascular diseases and, summary of findings, 1:28
in cerebrovascular disease etiology, 13:32-33
in chronic obstructive pulmonary disease etiology, 13:34-38
in coronary heart disease etiology, 13:32-33
effect of smoking duration on mortality ratio, 2:37
effect of smoking levels on lung neoplasm mortality, 13:27-28
effect of smoking levels on mortality, 13:14-17
effect of smoking levels on mortality ratio, 2:36-37
effect of use with other tobacco products on mortality ratio, 2:35-36, 2:39
effect on blood pressure, 13:34
effect on cholesterol levels in serum, 13:34
effect on laryngeal neoplasm mortality ratio, 13:24
effect on lung function, 13:34-35, 13:38
effect on lungs, 13:35
effect on mortality, 2:30, 2:35-37, 13:7-8, 13:13-14
effect on mortality rates, summary of findings, 1:27
effect on mortality ratios, 1:11-12
effect on neoplasm mortality ratios, 13:20
effect on oral neoplasm mortality ratios, 13:22
effect on pharyngeal neoplasm mortality ratios, 13:23
effect on respiratory symptoms, 13:36-37

emphysema and, 6:24-26
in lung neoplasm etiology, 13:28
NCSH survey in the United States, 13:8-9
neoplasms and, summary of findings, 1:27-28
nicotine absorption and, 13:17
oral neoplasms and, 5:39
peptic ulcer and, summary of findings, 1:28
in peptic ulcer etiology, 13:38
percent distribution in the United States, 13:9

SMOKING DURATION
age began smoking in males vs. females, 5:21, 5:22
bladder neoplasms and, 5:46
effect of age began smoking on lung neoplasm mortality ratio, 5:13-14
effect of age began smoking on mortality ratio, 2:19-21
effect on laryngeal neoplasm risk, 5:34
effect on lung neoplasm mortality ratio in women, 5:21-22
effect on mortality ratio, 2:17-19
effect on mortality ratio in cigar smokers, 2:37
effect on mortality ratio in ex-smokers, 2:28-29
effect on mortality ratio in pipe smokers, 2:38
effect on mortality ratio in women, 2:26-27
effect on myocardial infarct morbidity and mortality, 4:35

SMOKING HABIT
in blue- and white-collar workers, 7:17
carbon monoxide in maintenance, 15:15
carbon monoxide metabolism in maintenance, 15:17
central nervous system effects in establishment, 15:11
central nervous system effects in maintenance, 15:18
clinical importance in drug monitoring, 12:41-42
dependence in maintenance, 15:17-18
diurnal variations, 15:25-26
effect of β-blocker on cardiovascular system, 15:19
effect of β-blocker on central nervous system, 15:18-19
effect of β-blocker on hormones, 15:20
effect of blood circulation on maintenance, 15:19-20
effect of heredity, 15:9-10
effect of hormones, 15:10
effect of nicotine, 15:7-8
effect of nicotine, summary of findings, 1:30-92
effect of nicotine metabolism, 15:16
effect of nicotine self-administration in animals, 15:11-12
effect of tar, 15:7

Index of General Psychological Well-Being and, 3:17-18
lifestyle and, 3:11
lung neoplasms, occupational risk and race differences, 7:17
maintenance factors, 15:13
maternal, personality and, 8:26-27
nicotine in maintenance, 15:14
pharmacological aspects, 15:5
research issues, 4:22
role of carbon monoxide, 15:7
summary of behavioral and psychological research, 1:29-33
tar metabolism in maintenance, 15:17
tobacco metabolism and, 15:9
tobacco tars in maintenance, 15:15
trends in males vs. females in the United States, 5:19-21
women, 2:25-26, 5:19-21, 5:23

SMOKING LEVELS
(See also CIGARETTE CONSUMPTION)
school and, 3:10
asbestos exposure and fibrosis, 7:13
carboxyhemoglobin levels as indicator of self-reporting accuracy, 3:12
chronic obstructive lung disease and, 6:7, 6:10
effect on angina pectoris morbidity ratios, 4:48
effect on aortic aneurysm mortality ratios, 4:55
effect on atherosclerosis, 4:8-16
effect on bladder neoplasm risk, 5:45
effect on blood cholesterol levels, 4:62
effect on body weight during pregnancy, 8:24

smoking levels
(See also CIGARETTE CONSUMPTION)
school and, 3:10
asbestos exposure and fibrosis, 7:13
carboxyhemoglobin levels as indicator of self-reporting accuracy, 3:12
chronic obstructive lung disease and, 6:7, 6:10
effect on angina pectoris morbidity ratios, 4:48
effect on aortic aneurysm mortality ratios, 4:55
effect on atherosclerosis, 4:8-16
effect on bladder neoplasm risk, 5:45

transplant essentials, 9:10
effect on body weight during pregnancy, 8:24

summarize of behavioral and psychological research, 1:29-33
tar metabolism in maintenance, 15:17
tobacco metabolism and, 15:9
tobacco tars in maintenance, 15:15
trends in males vs. females in the United States, 5:19-21
women, 2:25-26, 5:19-21, 5:23

smoking levels
(See also CIGARETTE CONSUMPTION)
school and, 3:10
asbestos exposure and fibrosis, 7:13
carboxyhemoglobin levels as indicator of self-reporting accuracy, 3:12
chronic obstructive lung disease and, 6:7, 6:10
effect on angina pectoris morbidity ratios, 4:48
effect on aortic aneurysm mortality ratios, 4:55
effect on atherosclerosis, 4:8-16
effect on bladder neoplasm risk, 5:45

smoking levels
(See also CIGARETTE CONSUMPTION)
school and, 3:10
asbestos exposure and fibrosis, 7:13
carboxyhemoglobin levels as indicator of self-reporting accuracy, 3:12
chronic obstructive lung disease and, 6:7, 6:10
effect on angina pectoris morbidity ratios, 4:48
effect on aortic aneurysm mortality ratios, 4:55
effect on atherosclerosis, 4:8-16
effect on bladder neoplasm risk, 5:45

effect on blood cholesterol levels, 4:62
emphysema and radiation exposure and, 7:14
incidence of peptic ulcer and, 9:5
and lung pathology, 6:24
males vs. females, 5:21, 5:23
maternal, abruptio placentae, bleeding and placenta previa, 8:39
maternal, effect on birth weight, 8:12, 8:21, 8:25
maternal, effect on birth weight for gestational age, 8:20
maternal, effect on DDT content of breast milk, 8:51
maternal, effect on gestational age at birth, 8:43
maternal, effect on lactation, 8:50
maternal, effect on nicotine content of breast milk, 8:50
maternal, effect on perinatal mortality, 8:33
maternal, effect on perinatal mortality risk, 8:35
maternal, effect on weight gain and birth weight, 8:25
maternal, hyperkinesis in children and, 8:33
maternal, perinatal mortality and, 8:40
maternal, preeclampsia and toxemia and, 8:42
maternal, premature membrane rupture and, 8:39
maternal, sudden infant death syndrome and, 8:44-45
maternal, spontaneous abortion and, 8:30
maternal, synergism with other risk factors for perinatal mortality, 8:35
occupational exposure and health risk, 7:17
and pathological lesions of small airways, 6:19-19
prevalence of acute conditions and, 13:9
prevalence of chronic conditions and, 3:7
prevalence of peptic ulcer and, 9:6
respiratory symptoms and, 6:20
respiratory tract diseases in children and, 6:11
risk for respiratory tract infections and, 6:50
sex ratio in chronic obstructive pulmonary disease and, 6:20
SMOKING MACHINES
continuous vs. intermittent, 14:73
dosimetry, 14:74
SMOKING, MATERNAL
abortion and, 8:9, 8:30-32
abortion and, research needs, 8:77
abruptio placentae and stillbirth and, 8:39
anoxia and perinatal mortality and, 8:47
antepartum hemorrhage and, 8:39
bleeding during pregnancy and, 8:39
breast feeding and, 8:51
breast feeding and, research needs, 8:78-79
during pregnancy, and respiratory infection incidence in offspring, 11:32
effect of biologic factors on birth weight, 8:14-15
effect of smoking levels on birth weight, 8:12, 8:16
effect of smoking levels on placental ratio, 8:15, 8:18
effect of tobacco smoke on fetus and infant, mathematical model, 8:74
effect of socioeconomic factors on birth weight, 8:14-15
effect on behavioral development in children, 8:22
effect on behavioral, intellectual and physical development in children, 1:21
effect on bilirubin levels in neonate, 12:34
effect on birth weight, 8:9, 8:11-13, 8:17, 8:20-21, 8:26-27
effect on birth weight, research needs, 8:78
effect on birth weight, summary of findings, 1:21
effect on birth weight, summary of findings, 1:21
effect on birth weight for gestational age, 8:19-20
effect on body height in children, 8:21-23
effect on body weight during pregnancy, 8:24
effect on body weight in children, 8:21-23
effect on breastfed infants, 8:51
effect on duration of gestation, 8:18
effect on fetal and neonatal mortality, 8:41
effect on fetal breathing, 8:67
effect on fetal growth, 8:12, 8:18-19
effect on fetal growth, summary of findings, 1:21
effect on fetal growth in animals, research needs, 8:78
effect on fetal heart rate, 8:10, 8:67
effect on fetal thermogram, 8:68
effect on infant head and shoulder circumference, 8:19
effect on infant mortality, 8:10, 8:28
effect on intellectual development in children, 8:21 22
effect on lactation, 8:48, 8:50
effect on lactation, research needs, 8:73-79
effect on lactation, summary of findings, 1:22
effect on lymphocytotoxic antibodies, 10:18
effect on maternal and fetal carboxyhemoglobin levels, 8:70
effect on maternal weight gain and fetal growth, 8:24-25
effect on nicotine content of breast milk, 8:50-51
effect on neurological development in children, 8:21-22
effect on oxygen availability in mother and fetus, 8:17
effect on perinatal mortality, 8:32, 8:34-35
effect on perinatal mortality, summary of findings, 1:22
effect on physical development in children, 8:21-23
effect on placenta, 8:69
effect on placenta, research needs, 8:78
effect on placental metabolism, 8:96-69
effect on placental ratio, 8:14
effect on pregnancy, 8:9-11
effect on respiratory tract infection incidence in children, 10:12, 11:32
effect on umbilical artery, 8:69
effect on vitamin C levels in breast milk, 8:52
in etiology of fetal mortality, 8:38
in etiology of neonatal mortality, 8:38
in etiology of perinatal mortality in low birth weight infants, 12:67
hospital admission rates of children and, 11:33
hyperkinesis in children and, 8:23
hypotensive effect of thiocyanate levels, 8:42
incidence of low birth weight and, 8:12
long-term study of effects on children, research needs, 8:77
neonatal mortality and, research needs, 8:76
perinatal mortality risk and, 8:28
personality characteristics and, 8:96
placenta previa and, 8:39
pre-eclampsia and, research needs, 8:77
pregnancy complications and, research needs, 8:76-77
premature membrane rupture and, 8:39
prematurity and, 1:22
preterm delivery and infant mortality risk, 8:42
smoking levels and spontaneous abortion, 8:90
spontaneous abortion and, 8:9, 8:30-32
spontaneous abortion in wanted vs. unwanted pregnancy and, 8:30-32
stillbirth and, 8:36, 37
sudden infant death syndrome and, 8:44-45
sudden infant death syndrome and, research needs, 8:77
SMOKING, PARENTAL
(See also SMOKING, MATERNAL)
effect on asthmatic children, 10:21
effect on children, 11:31
effect on hospital admission rates of children and, 11:33
effect on respiratory tract infection incidence in children, 10:12
effect on youth, 17:5, 17:13, 21:13-14
maintenance of smoking and, 18:15
prevalence of respiratory disease in children and, 11:32-34
sudden infant death syndrome and, 8:45
SMOKING, PIPE
(See also SMOKE, PIPE; SMOKERS, PIPE; TOBACCO, PIPE)
in bronchial neoplasm etiology, 13:28-29
bronchopulmonary diseases and, summary of findings, 1:28

cardiovascular diseases and, summary of findings, 1:28

in cardiovascular disease etiology, 13:32-34

in cerebrovascular disease etiology, 13:32-33

in chronic obstructive pulmonary disease etiology, 13:34-35

in coronary heart disease etiology, 13:32-33

effect of smoking duration on mortality ratio, 2:38

effect of smoking levels on lung neoplasm mortality, 13:27-28

effect of smoking levels on mortality ratio, 2:36-38, 13:14-17

effect of use with other tobacco products on mortality ratio, 2:35-36, 2:39

effect on blood pressure, 13:34

effect on cholesterol levels in serum, 13:34

effect on lung function, 13:34-35, 13:38

effect on mortality rates, summary of findings, 1:27

effect on laryngeal neoplasm mortality ratios, 13:24

effect on mortality, 1:11-12, 2:30, 2:35-37, 13:7-8, 13:13-14

effect on mortality, summary of findings, 1:27

effect on oral neoplasm mortality ratios, 13:22

effect on pharyngeal neoplasm mortality ratios, 13:23

effect on respiratory symptoms, 13:36-37

emphysema and, 6:24-26

in ex-cigarette smokers, 19:29

in lip neoplasm etiology, 13:21

NCSH survey in the United States, 13:8-9

neoplasms and, summary of findings, 1:27-28

oral neoplasms and, 5:39

peptic ulcer and, summary of findings, 1:28

in peptic ulcer etiology, 13:38

percent distribution in the United States, 13:9

SMOKING PREVALENCE

adults in the United States, A:11, A:12-14

Health Interview Survey data, A:13

socioeconomic status and, A:15-16

teenagers in the United States, A:13-14

in white and black adults 1966-1976, A:15

SMOKING SURVEYS

adults in the United States 1949-1976, A:8-10


Health and Nutrition Examination Survey, 3:11-12

Health Interview Survey, 3:8-18

medical faculty of Dublin University College, 22:14

National Clearinghouse for Smoking and Health, 3:11

research design, 17:7

smoking and work-loss and bed-disability days, 3:8-18

teenagers in the United States 1966-1974, A:18

SMOKING WITHDRAWAL STUDY CENTRE (TORONTO)

group cessation program, 19:11

SNUFF

carbon monoxide as reinforcing agent, 15:7

consumption in the United States, 14:13

effect of manufacturing process, 14:30

effect on mouth mucosa in women, 13:39-40

in leukoplakia etiology, 13:49

in oral neoplasm etiology, 13:39-40

prevalence of use in the United States, 13:10, 13:39

tobacco selection, processing and manufacture, 13:38-39

SNUFF DIPPING

(see also SMOKING)

health effects, summary of findings, 1:29

SOCIAL FACTORS

effect on mortality, 2:42
SOCIOECONOMIC STATUS
cessation of smoking and, 18:20-22
recidivism and, 19:31
smoking and chronic obstructive lung
disease, 6:38
smoking in adolescents and, 17:8
smoking prevalence in adults and,
A:15-16, 18:16

SOIL
effect on metal levels in tobacco,
14:58
effect on tobacco quality, 14:16

STANFORD HEART DISEASE PREVENTION PROGRAM
effect on cessation of smoking,
19:15-16, 21:24-25

STILLBIRTH
maternal smoking and, 8:36-37
etiology of, in smokers vs. nonsmokers,
8:36-37
maternal smoking and abruptio placentae and,
8:39
in smokers vs. nonsmokers, 8:36

STIMULUS CONTROL TREATMENT
modification of smoking behavior,
16:16, 19:20-21, 19:29

STRESS
(See also ANXIETY)
nicotine excretion and, 16:8

STROKE
oral contraceptives and smoking and,
12:51
smoking and, 4:50, 4:52

STRUCTURAL FORMULA
carcinogenic polynuclear aromatic hydrocarbons,
14:53
catechol, 14:56
heterocyclic compound carcinogens,
14:55
isoprenoids, 14:50
mafic hydrizide, 14:52
nicotine, 14:46
nicotine metabolic pathway, 14:93
nitrosamines, 14:46
pesticides in cigarette smoke, 14:82
pesticides in tobacco, 14:62
phenol, 14:56
tobacco alkaloids, 14:46, 14:95
weakly acidic heterocyclic compounds
in cigarette smoke, 14:56

STUDENTS, COLLEGE
alcohol, marijuana, and tobacco use,
18:14
health education opportunities, 21:9-11
smoking habits, 22:18

SUBARACHNOID HEMORRHAGE
effect of smoking and oral contraceptives on risk, 4:50, 4:60-61

SUDDEN CARDIAC DEATH
coronary heart disease and, 4:41-43
effect of smoking levels on mortality ratios, 4:43
induced by cholesterol and ischemia
in primates, 4:43
research needs, 4:45
risk factors, 4:43-44
smokers vs. nonsmokers, 4:43-44
smoking in etiology of, 4:44-45

SUDDEN INFANT DEATH SYNDROME
effect of maternal smoking, 8:44-45
maternal smoking levels and, 8:44-45
research needs, 8:77

SULFUR COMPOUNDS
levels in cigarette smoke, 14:40

SWEDISH TWIN REGISTRY
mortality ratios in smokers, 2:42

SYSTEMATIC DESENSITIZATION
modification of smoking behavior,
19:22

TAR CONTENT
of cigarettes and health characteristics, 3:11
decrease in modern cigarettes, A:19-20
sales weighted average per cigarette
1954-1977, A:19

TABS, CIGAR
carcinogenicity, 13:30-32
in cigars, 14:44

TABS, CIGARETTE
and beta radiation induced skin carcinoma in mice, 7:10
determination in mainstream smoke, 14:43
effect on mortality, 2:22
effect on smoking habit, 15:7
metabolism in maintenance of smoking habit, 15:17
polynuclear aromatic hydrocarbons
and, 14:52
reduction, effect on lung neoplasm
mortality ratio, 5:15 16
reduction in particulate phase cigarette smoke, 14:108
reduction methods, 14:110
sales weighted average delivery in the United States, 14:109
summary of constituents, 1:29-30
TARS, PIPE
carcinogenicity, 13:30-32
TARS, TOBACCO
(See also PARTICULATE PHASE, CIGARETTE SMOKE; TARS, CIGAR; TARS, CIGARETTE; TARS, PIPE; TOTAL PARTICULATE MATTER)
carcinogens, cocarcinogens and tumor promoters, 5:54-57
in maintenance of smoking habit, 15:15
TEACHERS
attitudes and smoking habits of coaches, 21:13
attitudes toward school smoking in principals, 23:14
attitudes toward smoking education, 21:12-13
health education certification requirements, 23:22-31
as role models, 17:15, 21:12-13, 23:11-12, 23:55-36
school smoking policies, 23:8-12
smoking habits, 23:35-36
training in adult education, 21:9
training in health education, 20:19-20, 21:11, 21:19-21
TEENAGERS
(See also ADOLESCENTS)
cigarette consumption patterns in the United States, A:23
female, increase in smoking prevalence, A:14
smoking prevalence data, A:13-14
smoking surveys in the United States 1968-1974, A:18
TERMperature Profiles
effect of cigarette composition and size, 14:35
TETRAHYDROCANNABINOL
(See also CANNABIS)
effect on enzyme activity, 12:42-43
THEOPHYLLINE
effect of methylcholanthrene on metabolism in rats, 12:32
pharmacokinetics in smokers vs. non-smokers, 12:31-32
THERMAL ENERGY ANALYZER
in tobacco analysis, 14:9
THIOCYANATE LEVELS
(See also CYANIDES)
in clinical determination of smoking levels, 12:42
in plasma of smokers vs. nonsmokers, 7:7
maternal smoking and hypotensive effect, 8:42
monitoring in cessation studies, 19:7, 19:20, 19:28
in saliva of smokers vs. nonsmokers, 15:30
in urine of smokers vs. nonsmokers, 7:7
THROMBOANGIITIS OBLITERANS
(See also THROMBOSIS)
allergy and, 4:60
atherosclerosis and, 4:60
clinical and pathological features, 4:60
role of tobacco proteins in etiology of, 4:60
smoking and, 4:60
THROMBOEMBOLISM
oral contraceptives and smoking and, 12:31
THROMBOSIS
(See also CARDIOVASCULAR DISEASES; CORONARY HEART DISEASE; THROMBOANGIITIS OBLITERANS)
mortality rates in cigar and pipe smokers, 4:59
mortality rates in smokers vs. non-smokers, 4:59
research needs, 4:59
smoking and, 4:59
smoking and oral contraceptives and, 4:59
TOBACCO
(See also TOBACCO CHEWING; TOBACCO, CIGAR; TOBACCO, CIGARETTE; TOBACCO, PIPE)
allergic effects on cardiovascular system, 10:22-23
allergy and, summary of findings, 1:23-24
in allergy etiology, 10:23-24
amine and nitrosamine content, 12:74
antigen, role in immunoglobulin disease entities, 10:7
antigenicity of, 10:310
blends in cigarette manufacturing, effect on smoke constituents, 14:29
carcinogenesis induction in animals, 5:55-56

carcinogenesis induction in animals,
summary of methods, 5:29-30
constituents, in main- vs. sidestream smoke, 11:5-6
constituents, effect with occupational exposure on health, 7:7-9
consumption, historical trends in the United States, 1:5
immune hyperresponsiveness, 10:20
isoprenoid levels, 14:48-49
male vs. female consumption in the United States, 14:13
metabolism in smokers vs. nonsmokers, 15:9
pesticide residue reduction, 14:61
production by type in the United States 1964-1975, 14:12
radioelement levels, 14:60
stems, used in cigarette manufacturing in the United States, 14:13
types, components after aging, 14:21
types, production in the United States 1964-1975, 14:12
types and classes, 14:13-15
types used in smoking products, 14:14
usability index, 14:23
usage measuring techniques, 15:28-31
worldwide production levels, 14:11

TOBACCO ADDITIVES
effect on percent weight of products, 14:63
use in chewing tobacco and snuff, 13:39

TOBACCO AGING
effect on components of tobacco types, 14:21
effect on taste and aroma, 14:19
methods, 14:19

TOBACCO CHEWING
(See also BETEL CHEWING)
carbon monoxide as reinforcing agent, 15:7
consumption in the United States, 14:13
effect of manufacturing process, 14:30
health effects, summary of findings, 1:29
leukoplakia and, 5:41
in leukoplakia etiology, 13:40-41
nitrosamines and, 14:45
in oral neoplasm etiology, 13:40-41
oral neoplasms and, 5:39-40
prevalence in the United States, 13:10, 13:39
tobacco selection, processing and manufacture, 13:38-39

TOBACCO, CIGAR
(See also CIGARS; SMOKE, CIGAR; SMOKERS, CIGAR; SMOKING, CIGAR)
components after fermentation, 14:22
storage and fermentation, 14:19-20
U.S. government definition, 13:10

TOBACCO, CIGARETTE
(See also CIGARETTES; SMOKE, CIGARETTE; SMOKERS; SMOKING)
United States Government definition, 13:10

TOBACCO, PIPE
(See also SMOKE, PIPE; SMOKERS, PIPE; SMOKING, PIPE)
consumption in the United States, 14:13
effect of manufacturing process, 14:30
United States Government definition, 13:11

TOBACCO COMBUSTIBILITY
(See also TOBACCO PYROLYSIS)
growth conditions and, 14:16-17
precursors of smoke constituents with tumor activity and, 14:23

TOBACCO CONTAMINANTS
aflatoxin B1, 14:22
pesticides, effect on smoking quality, 14:18
radioelements, 14:20-21

TOBACCO CULTURE
chemical conversions, 14:19-20
effect on tobacco leaf components, 14:16-17
effect on tobacco quality, 14:16
harvesting and tobacco quality, 14:17-18
methods for quality improvement, 14:17-18
TOBACCO CURING
  effect on nitrosamine levels, 14:45
  effect on polonium-210 content, 14:313
  homogenized leaf curing, 14:19, 14:26
  maleic hydrazide and, 14:47
  methods, 14:19
  nicotine reduction and, 14:108
  tar reduction and, 14:108
Tobacco extracts
  See TOBACCO LEAF EXTRACTS
TOBACCO INDUSTRY
  economic impacts, 21:18
TOBACCO LEAF
  alkane content, 14:48
  allergies in tobacco workers, 10:20
  antigens, 10:11
  characteristics, as "markers" for
  smoke delivery and composition, 14:22-23
  characteristics, correlations with
  smoke constituents, 14:24
  characteristics and biological re-
  sponse, 14:25
  classes produced in the United
  States, 14:14
  combustibility and growth conditions,
  14:16-17
  components, 14:16
  components, effect of tobacco cul-
  ture, 14:16-17
  components, fraction-1-protein as
  food source, 14:28
  components, modification, 14:30
  effect of aging, 14:19
  effect of cultivation conditions on
  smoking quality, 14:15-16
  effect of curing, 14:19
  effect of growth conditions on com-
  ponents, 14:16-17
  effect of stalk position on com-
  ponents, 14:18, 14:20
  effect of stalk position on quality,
  14:17-18, 14:20
  effect on mainstream smoke composi-
  tion, 14:38
  effect on smoke components, 14:11
  "markers", and modification of bio-
  logical effect, 14:25
  nicotine levels, 14:45
  nonvolatile nitrosamine levels, 14:45
  physical and chemical characteristics
  affecting smoking quality, 14:14-
  16
  relation of chemical components to
  smoking quality, 14:20
  United States Government grading
  system, 14:14
TOBACCO LEAF EXTRACTS
  in allergy desensitization injections,
  10:15
  antigenicity, 10:10
  in carcinogenesis induction in ani-
  mals, summary of methods, 5:29-
  30
  skin test reactions in allergic vs.
  nonallergic children, 10:15
  skin test reactions in asthmatic pa-
  tients, 10:10
  skin test reactions in smokers vs.
  nonsmokers, 10:13
TOBACCO PROTEINS
  allergic and irritant reactions, 10:13
  antigenicity, 10:11
  effect on blood coagulation, 4:60
  role in thromboangiitis obliterans eti-
  ology, 4:60
  skin test reactions, 10:12
TOBACCO PYROLYSIS
  (See also TOBACCO COMBUSTI-
  BILITY)
  aromatic hydrocarbon reduction and,
  14:111
  benzene levels and, 14:49
  naphthalene levels and, 14:49
  Tobacco reconstituted
    See TOBACCO SHEET
TOBACCO SHEET
  carcinogenicity, 14:29
  ciliotoxicity, 14:105
  economic effect on industry, 14:27
  effect on tobacco product manufac-
  turing, 14:27
  tar levels and, 14:44
  technological advances, 14:9
  in cigarette manufacturing in the
  United States, 14:13
  in tobacco product manufacturing,
  14:27
Tobacco smoke
See SMOKE, TOBACCO

TOBACCO SUBSTITUTES
ciliotoxicity, 14:105
smoking habit and, 15:8

TOBACCO TYPES
carboxylic acid levels, 14:57
in chewing tobacco, 13:30
in cigarette manufacturing in the
United States, 14:13, 14:14
production in the United States,
1964-1975, 14:12
tar levels, 14:44

TOBACCO WITHDRAWAL SYNDROME
degree of deprivation and, 15:27
dependency and, 15:24-25
severity in males vs. females, 15:28
summary of findings, 1:32
time course, 15:26

TOBACCO WORKERS
abortion, 8:9
allergic asthma, 10:21
allergies to tobacco leaf products,
10:20
contact dermatitis, 10:23

TOLERANCE
to carbon monoxide in maintenance
of smoking habit, 15:15
to cigarette smoke in smokers vs.
nonsmokers, 15:16-17
effect of smoke inhalation in dogs,
15:16
to tobacco in maintenance of smok-
ing habit, 15:13-15

TONGUE NEOPLASMS
(See also MOUTH NEOPLASMS)
alcohol consumption and smoking
and, 5:41

TOTAL PARTICULATE MATTER
(See also PARTICULATE PHASE,
CIGARETTE SMOKE; TARS, TO-
BACCO)
carcinogens, 14:65
effect of homogenized leaf curing,
14:27
levels in cigar smoke, 13:11
nicotine reduction, 14:108
tar levels, 14:44

TOXEMIA
maternal smoking levels and, 8:42

TRACHEA
(See also RESPIRATORY
SYSTEM)
effect of cigar smoke on cilia in
cats, 13:37
in smoke inhalation methodology,
14:74

TRACHEAL NEOPLASMS
(See also RESPIRATORY TRACT
NEOPLASMS)
in hamster offspring after nitroso-
mine injection of lactating moth-
ers, 8:50
induced by nitrosamines in animals,
5:30

TRACHEOBRONCHIAL CLEARANCE
(See also MUCOCILIARY
SYSTEM)
effect of tobacco smoke in dogs,
10:15

TRYPTOPHAN METABOLISM
bladder neoplasms and, 5:47
smokers vs. nonsmokers, 12:67

TUMOR PROMOTERS
(See also CARCINOGENS; COCAR-
CINOGENS)
role in carcinogenesis, 5:54
in tobacco smoke gas phase, 5:54-55
in tobacco smoke particulate phase,
5:54-55, 5:57

TWINS
lung neoplasm mortality in smokers
vs. nonsmokers, 2:42
mortality ratio in smokers, 2:42
smoking habit and heredity, 15:9-10

ULCER, PEPTIC
cigar and pipe smoking and, summa-
ry of findings, 1:28
cigar and pipe smoking in etiology
of, 13:38
economic impact in the United
States, 9:17
effect of smoking on bile reflux,
9:16
effect of smoking on healing, 9:9
effect of smoking on mortality in
males, 9:10-11
effect of smoking on size, healing,
and recurrence, 9:8-9
epidemiology, 9:5
etiology, 9:11-12, 9:16-17
healing in smokers vs. nonsmokers, 9:10
incidence in the United States, 9:17
mortality in cigar vs. cigarette vs. pipe smokers, 13:38
mortality in smokers, 2:41
prevalence in male and female smokers and nonsmokers, 9:6-7, 9:8, 9:17
prevalence in Poland, 9:6
prevalence ratios in six countries, 9:8
role of nicotine in induction, 9:12-13
smoking, coffee and alcohol consumption and, 9:6
smoking and, summary of findings, 1:23
smoking in etiology of, 9:11-12
smoking levels and prevalence of, 9:6
UNIVERSITY OF ILLINOIS ANTI-SMOKING EDUCATION STUDY
description, 20:15-18
evaluation, 17:20, 20:11
teaching approaches, 23:26-27
URANIUM
and smoking in lung neoplasm etiology, 5:28
synergistic effect with smoking on respiratory tract, 12:90
URETHANE
in cigarette smoke, 14:41
URINE
acidity and nicotine excretion, 16:8
effect of pH on nicotine metabolism, 14:32-33
nicotine content as measure of tobacco usage, 15:29
USABILITY INDEX
tobacco leaf "markers" in development, 14:23
VENTILATION RATE
effect on eye irritation, 11:26-27
VERBAL REPORTS
(See also SELF REPORTS)
as measure of tobacco usage, 15:31
Ventilatory function tests
(See RESPIRATORY FUNCTION TESTS)
VETERANS ADMINISTRATION
recommendations for smoking control by health professionals, 22:22-23

Vital capacity measurements
See RESPIRATORY FUNCTION TESTS

VITAMIN B12 LEVELS
effect of smoking, 12:67
VITAMIN B6 levels, effect of smoking, 12:66
levels in pregnant smokers vs. nonsmokers, 8:73
tobacco amblyopia and, 12:66
VITAMIN C LEVELS
in breast milk, effect of maternal smoking, 8:52
effect of nicotine in animals, 12:66
effect of smoking, 12:66
in pregnant smokers vs. nonsmokers, 8:74
in smokers vs. nonsmokers, 12:64, 12:66
VITAMIN DEFICIENCY
smoking in etiology of, 12:66-67

WARFARIN
effect of benzo(a)pyrene on pharmacokinetics in rats, 12:38
effect of smoking on metabolism, 12:55
pharmacokinetics in smokers vs. nonsmokers, 12:38

WEIGHT GAIN
and smoking cessation, 19:31
WITHDRAWAL CLINICS
(See also CESSATION OF SMOKING)
effectiveness, 19:10-12, 19:15
evaluation design, 19:33-34, 19:36
sponsored by voluntary agencies, 21:16

WITHDRAWAL STATE
and maintenance of nonsmoking, 19:31
neuroticism and, 18:9
recidivism and, 16:18
as reinforcer of smoking, 16:10-11
symptoms, 16:14

WOMEN
(See also SEX RATIO)
acute conditions in smokers vs. nonsmokers, 3:8
cigarette consumption patterns in the
United States, A:28
effect of inhalation, smoking duration and smoking levels on mortality ratio, 2:26-27
effect of less hazardous cigarettes on mortality ratios, 2:23-24
effect of smoking on mortality, 2:25-27
laryngeal neoplasm risk in ex-smokers, 5:38
laryngeal neoplasm risk in smokers, 5:36
lung neoplasm mortality rates, 5:16-18, 5:20
lung neoplasm mortality ratio in smokers, 5:20-22
myocardial infarct in smokers vs. nonsmokers, 4:30-36, 12:52
severity of tobacco withdrawal syndrome, 15:28
smoking habit, 2:25-62, 5:19-21, 5:23
smoking prevalence, A:11, A:12-18, A:17-18

WOMEN'S CHRISTIAN TEMPERANCE UNION
antismoking campaign, 23:12-13

WOMEN'S MOVEMENT
influence on adolescent smoking, 18:16-17
influence on smoking habits, 17:13
and sex differences in cessation of smoking, 18:21

WORKPLACE PROGRAMS
antismoking campaigns, 7:18-19
coronary prevention programs, 22:16-17, 22:19
modification of smoking behavior, 13:9-10, 13:28-29

WORLD HEALTH ORGANIZATION
report on antismoking legislation, 21:18

YMCA
antismoking programs, 20:24

ZINC LEVELS
smokers vs. nonsmokers, 12:73